| 摘要 |
The present invention is directed to adenoviral vectors having modified capsid proteins which comprise heterologous ligands that improve and/or alter the infectious capability of the vector. Such ligands are capable of binding to target cells, and their inclusion into adenoviral vectors facilitates the binding and infectious properties of the vectors. In a preferred embodiment, the ligands are peptides, and the target cells are epithelial cells. The invention is also directed to novel heterologous ligands, to ligand-receptor complexes, and to compositions comprising the adenoviral vectors of the invention. Additional aspects of the invention include methods to use the adenoviral vectors of the invention to deliver transgenes to target cells. |
